Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Saudi Arabia pharmaceutical drugs market includes medicinal products sold as patented/prescription and OTC products for various ailments in hospitals and retail pharmacies. Patented products are available as branded drugs and generic drugs include both branded generics and non-branded ones.

Strategic agreements with multinational pharmaceuticals are expected to boost growth of the Saudi Arabia pharmaceutical market. For instance, in April 2020, SPIMACO Addwaeih signed an agreement with Amgen Inc. (a U.S.-based company) to localize the marketing rights and transfer the technology of some manufacturing steps of high quality biotechnology products that are used to treat immunological diseases. This is in line with Saudi Arabia's Vision 2030 to encourage the localization of high technology in the pharmaceutical industries.

The Saudi Arabia pharmaceutical drugs market is estimated to be valued at US$ 10,191.4 million in 2020 and is expected to exhibit a CAGR of 7.3% during the forecast period (2020-2027).

Saudi Arabia Pharmaceutical Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

New Development

Factors such as investments, research and development of novel medicines targeting COVID 19 as well as funding by various companies operating in Saudi Arabia pharmaceuticals drugs market are expected to drive the Saudi Arabia pharmaceuticals drugs market growth during this COVID 19 pandemic.

For instance, in March 2020, the government of Saudi Arabia announced that it donated US$ 10 million as financial support to the World Health Organization (WHO). The money is allocated for research and development of vaccines, diagnostics, and therapeutics.

In April 2020, the Coalition for Epidemic Preparedness and Innovations (CEPI) and Gavi, the Vaccine Alliance announced that the Group 20 of Kingdom of Saudi Arabia committed US$ 150 million for development of COVID-19 vaccine and invested in the manufacturing capacity required to produce a safe and effective vaccine for covid-19 infection. CEPI is working with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland, and a consortium led by Institut Pasteur for COVID-19 vaccine development projects.

Strategies

The coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID 19 pandemic. Saudi Arabia Government, multinational pharmaceutical companies, and local manufacturers are implementing various strategies to help the residents of Saudi Arabia during this COVID-19 pandemic.

For instance, in April 2020, Saudi Arabia's National Unified Procurement Company (NUPCO) and a Chinese company ‘Huo-yan Laboratories’ - COVID-19 testing labs developed by Chinese genomics BGI Group, signed a cooperation agreement in Riyadh to build six major laboratories including a mobile laboratory to increase the country's coronavirus testing capacity. After finishing, the laboratories will boost local coronavirus testing capacity to 50,000 people per day and provide 9 million testing kits.

Figue 1: Saudi Arabia Pharmaceutical Drugs Market Share (%) Analysis, By Drug Type, 2020

Saudi Arabia Pharmaceutical Drugs  | Coherent Market Insights

The major companies operating in Saudi Arabia pharmaceutical drugs market are focused on adopting strategies such as collaborations and partnerships for development of drugs, R&D activities, and geographic expansions, which is expected to boost the Saudi Arabia pharmaceutical drugs market growth

For instance, in May 2016, GE Healthcare entered into a vaccine collaboration with the National Industrial Clusters Development Program (NICDP) under the Ministry of Energy, Industry and Mineral Resources, SaudiVax, and King Saud University, to enable vaccine self-sufficiency and pandemic preparedness in the Kingdom of Saudi Arabia (KSA).

Major players in the market are focused on partnering with educational institutes for development of novel drugs to treat various diseases. For instance, in April 2017, SPIMACO and King Saud University signed a memorandum of understanding in the fields of drug development and training of graduates of the Faculty of Pharmacy. The deal also aims to promote the profession of pharmacy and provide treatment services by trainee students in community pharmacies.

Other prominent players in the market are engaged in adopting partnership strategies to expand their geographic presence in Saudi Arabia. For instance, in February 2020, Grifols, a Spain-based pharmaceutical company and the Public Investment Fund of Saudi Arabia announced a deal to build a network of plasma collection centers and other facilities for the production of plasma medicines in Saudi Arabia.

request-sample

Saudi Arabia Pharmaceutical Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 10,191.4 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 7.3% 2027 Value Projection: US$ 16,663.1 Mn
Geographies covered:
  • Saudi Arabia
Segments covered:
  • By Drug Type: Generic Drugs, Branded Drugs.
  • By Product Type: Prescription Drugs, Over-the-counter (OTC) Drugs.
  • By Application: Cardiovascular, Musculoskeletal, Oncology, Anti-infective, Metabolic Disorder, Central Nervous System, Gastrointestinal, Respiratory, Hematology, Dermatology, Ophthalmology, Others (Nutraceutical, dentals and veterian).
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.
Companies covered:

Pfizer, Inc. ,Sanofi S. A., GlaxoSmithKline Plc., AstraZeneca Plc, Baxter International Inc., Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals, Hikma Pharmaceuticals PLC, Jamjoom Pharmaceuticals Co., and Julphar

Growth Drivers:
  • Rapid Reforms in the Healthcare Sector of Saudi Arabia
  • Increasing Collaborations and Partnerships
  • Drug Launches and Approvals
Restraints & Challenges:
  • Frequent Drug Recalls and High Reliance on Imports

Saudi Arabia Pharmaceutical Drugs Market - Restraints

Saudi Arabia pharmaceutical drugs market growth is expected to be hampered in the near future, owing to increasing drug recalls by the Ministry of Health (MOH) Saudi Arabia.

For instance, in August 2019, Julphar (a Saudi Arabia-based pharmaceutical company) recalled a single batch of Laxocodyl suppository (10mg) due to a labeling error on the blister pack. Laxocodyl is used to treat constipation in adults, however, the label on the blister pack in batch 0093 incorrectly stated that the product is for children. The company, in full cooperation with the UAE Ministry of Health and Prevention, issued an immediate order to recall the batch and worked with its distributors to ensure that all boxes in the specified batch were returned.

Figure 2: Saudi Arabia Pharmaceutical Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Saudi Arabia Pharmaceutical Drugs  | Coherent Market Insights

Saudi Arabia Pharmaceutical Drugs Market - Competitive Landscape

Key players operating in the Saudi Arabia pharmaceutical drugs market include Pfizer, Inc., Sanofi S. A., GlaxoSmithKline Plc., AstraZeneca Plc, Baxter International Inc., Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals, Hikma Pharmaceuticals PLC, Jamjoom Pharmaceuticals Co., and Julphar.

Saudi Arabia pharmaceutical drugs market growth is driven by various factors such as population growth, investment in halal pharmaceuticals, decrease in fertility rates, and increase in life expectancy. The market is witnessing increasing investment by major market players and several local and international companies are collaborating with local generic manufacturers. Such factors are expected to facilitate robust, stable, organic growth of Saudi Arabia pharmaceutical drugs market over the forecast period.

Market Dynamics

The healthcare sector of Saudi Arabia is witnessing significant reforms, owing to increasing initiatives by the government, agreements between multinational pharmaceutical companies, and rising healthcare expenditure, which is expected to drive growth of the Saudi Arabia pharmaceutical drugs market.

Rapid reforms in the healthcare sector in Saudi Arabia by the government and multinational companies is expected to propel growth of the Saudi Arabia pharmaceuticals drugs market. For instance, in March 2020, The Ministry of Health of Saudi Arabia signed a memorandum of understanding with Sanofi Saudi Arabia, to start localizing and transferring insulin industry technology locally in the Kingdom of Saudi Arabia and the possibility of external export to the GCC countries and the Middle East region.

In July 2019, Saudi Arabian General Investment Authority (SAGIA) signed a manufacturing localization agreement with British pharmaceutical giant Glaxosmithkline (GSK) that will see the latter double its manufacturing capacity by 2022, creating various national-oriented jobs in Saudi Arabia.

Key features of the study:

  • This report provides in-depth analysis of the Saudi Arabia pharmaceutical drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the Saudi Arabia pharmaceutical drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Pfizer, Inc., Sanofi S. A., GlaxoSmithKline Plc., AstraZeneca Plc, Baxter International Inc., Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals, Hikma Pharmaceuticals PLC, Jamjoom Pharmaceuticals Co., and Julphar
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The Saudi Arabia pharmaceutical drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for pharmaceutical drugs, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Saudi Arabia Pharmaceutical Drugs Market, By Drug Type:
    • Generic Drugs
    • Branded Drugs
  • Saudi Arabia Pharmaceutical Drugs Market, By Product Type:
    • Prescription Drugs
    • Over-the-counter (OTC) Drugs
  • Saudi Arabia Pharmaceutical Drugs Market, By Application:
    • Cardiovascular
    • Musculoskeletal
    • Oncology
    • Anti-infective
    • Metabolic Disorder
    • Central Nervous System
    • Gastrointestinal
    • Respiratory
    • Hematology
    • Dermatology
    • Ophthalmology
    • Others (Nutraceutical, dentals and veterian)
  • Saudi Arabia Pharmaceutical Drugs Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Saudi Arabia Pharmaceutical Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Generic Drugs
        • Branded Drugs
      • By Product Type:
        • Prescription Drugs
        • Over-the-counter (OTC) Drugs
      • By Application:
        • Cardiovascular
        • Musculoskeletal
        • Oncology
        • Anti-infective
        • Metabolic Disorder
        • Central Nervous System
        • Gastrointestinal
        • Respiratory
        • Hematology
        • Dermatology
        • Ophthalmology
        • Others (Nutraceutical, dentals and veterian)
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Europe
      • By Country:
        • K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Generic Drugs
        • Branded Drugs
      • By Product Type:
        • Prescription Drugs
        • Over-the-counter (OTC) Drugs
      • By Application:
        • Cardiovascular
        • Musculoskeletal
        • Oncology
        • Anti-infective
        • Metabolic Disorder
        • Central Nervous System
        • Gastrointestinal
        • Respiratory
        • Hematology
        • Dermatology
        • Ophthalmology
        • Others (Nutraceutical, dentals and veterian)
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Generic Drugs
        • Branded Drugs
      • By Product Type:
        • Prescription Drugs
        • Over-the-counter (OTC) Drugs
      • By Application:
        • Cardiovascular
        • Musculoskeletal
        • Oncology
        • Anti-infective
        • Metabolic Disorder
        • Central Nervous System
        • Gastrointestinal
        • Respiratory
        • Hematology
        • Dermatology
        • Ophthalmology
        • Others (Nutraceutical, dentals and veterian)
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Generic Drugs
        • Branded Drugs
      • By Product Type:
        • Prescription Drugs
        • Over-the-counter (OTC) Drugs
      • By Application:
        • Cardiovascular
        • Musculoskeletal
        • Oncology
        • Anti-infective
        • Metabolic Disorder
        • Central Nervous System
        • Gastrointestinal
        • Respiratory
        • Hematology
        • Dermatology
        • Ophthalmology
        • Others (Nutraceutical, dentals and veterian)
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Generic Drugs
        • Branded Drugs
      • By Product Type:
        • Prescription Drugs
        • Over-the-counter (OTC) Drugs
      • By Application:
        • Cardiovascular
        • Musculoskeletal
        • Oncology
        • Anti-infective
        • Metabolic Disorder
        • Central Nervous System
        • Gastrointestinal
        • Respiratory
        • Hematology
        • Dermatology
        • Ophthalmology
        • Others (Nutraceutical, dentals and veterian)
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Generic Drugs
        • Branded Drugs
      • By Product Type:
        • Prescription Drugs
        • Over-the-counter (OTC) Drugs
      • By Application:
        • Cardiovascular
        • Musculoskeletal
        • Oncology
        • Anti-infective
        • Metabolic Disorder
        • Central Nervous System
        • Gastrointestinal
        • Respiratory
        • Hematology
        • Dermatology
        • Ophthalmology
        • Others (Nutraceutical, dentals and veterian)
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
  • Company Profiles
    • Pfizer, Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Sanofi S. A.
    • GlaxoSmithKline Plc.
    • AstraZeneca Plc
    • Baxter International Inc.
    • Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
    • Tabuk Pharmaceuticals
    • Hikma Pharmaceuticals PLC
    • Jamjoom Pharmaceuticals Co.
    • Julphar

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Epidemiology
    • Regulatory Scenario
    • Reimbursement Scenario
    • Patent Approval
    • Pipeline Analysis
    • Product Approvals And Launches
    • PEST Analysis
  4. Impact Analysis of Covid-19
    • Pre COVID-19 Market Situation
    • Post COVID-19 Market Situation
    • New Developments
    • Strategies
  5. Saudi Arabia Pharmaceutical Drugs Market, By Drug Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Generic Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Branded Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Saudi Arabia Pharmaceutical Drugs Market, By Product Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Prescription Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Over-the-counter (OTC) Drugs
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Saudi Arabia Pharmaceutical Drugs Market, By Application, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Cardiovascular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Musculoskeletal
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Oncology
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Anti-infective
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Metabolic Disorder
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Central Nervous System
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Gastrointestinal
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Respiratory
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hematology
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Dermatology
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Ophthalmology
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others (Nutraceutical, dentals and veterian)
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Saudi Arabia Pharmaceutical Drugs Market, By Distribution Channel , 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  9. Saudi Arabia Pharmaceutical Drugs Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  10. Competitive Landscape
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S. A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Baxter International Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Tabuk Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hikma Pharmaceuticals PLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Jamjoom Pharmaceuticals Co.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Julphar
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 44 market data tables and 43 figures on "Saudi Arabia Pharmaceutical Drugs Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the Saudi Arabia pharmaceutical drugs market is expected to be 7.3% during the forecast period (2020-2027).
The value of Saudi Arabia pharmaceutical drugs market is estimated to be US$ 10,191.4 million in 2020.
The prominent players in the Saudi Arabia pharmaceutical drugs market include Pfizer, Inc. ,Sanofi S. A., GlaxoSmithKline Plc., AstraZeneca Plc, Baxter International Inc., Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals, Hikma Pharmaceuticals PLC, Jamjoom Pharmaceuticals Co., and Julphar.
The Saudi Arabia pharmaceutical drugs market is expected to be valued at US$ 16,663.1 million in 2027.
Increasing collaborations and partnerships, and drug launches and approvals are expected to drive growth of the Saudi Arabia pharmaceutical drugs market.
Prescription Drugs segment is expected to hold the highest market share in the Saudi Arabia pharmaceutical drugs market
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner